The DUSP3 Knockout MES-OV Polyclonal Cells are a pooled CRISPR/Cas9-edited cell population derived from the MES-OV ovarian cancer line. Targeting the DUSP3 gene, this polyclonal knockout product comprises a heterogeneous mixture of cells with diverse genetic disruptions at the DUSP3 locus, resulting in loss of DUSP3 protein expression. The polyclonal format avoids clonal selection bias, offering a robust model for studying DUSP3-dependent signaling and phenotypes at the population level.
The parental MES-OV cell line was established from the ascitic fluid of a patient with ovarian clear cell adenocarcinoma, a subtype of epithelial ovarian cancer characterized by resistance to conventional therapies. MES-OV retains key features of this malignancy, including aberrant growth factor signaling. This background provides a clinically relevant context for investigating the consequences of DUSP3 loss and MAPK pathway hyperactivation in ovarian clear cell carcinoma.
DUSP3 (VHR) is a dual-specificity phosphatase that dephosphorylates MAP kinases ERK1/2 (MAPK1) and JNK1 (MAPK8), acting as a negative regulator of the EGFR?CRas?CMAPK signaling axis. Upstream regulators include EGFR activation, Ras GTPases, growth factors, and oxidative stress. DUSP3-mediated dephosphorylation attenuates signaling through the RAF?CMEK?CERK and JNK cascades, reducing phosphorylation of downstream effectors such as ELK1 and c-JUN. In the knockout state, sustained kinase activity promotes pro-proliferative and survival transcriptional programs.
In ovarian clear cell carcinoma, DUSP3 downregulation correlates with tumor progression, and its knockout in MES-OV cells recapitulates a tumor-suppressor loss-of-function. The absence of DUSP3 leads to persistent ERK1/2 and JNK activation, driving enhanced proliferation, survival, and invasive potential??phenotypes central to disease aggressiveness. This model enables dissection of DUSP3’s role in counteracting EGFR-driven oncogenic signals and provides a platform for evaluating molecular dependencies in clear cell ovarian cancer.
This polyclonal knockout population is suitable for western blot analysis of phospho-ERK1/2 and phospho-JNK, MTS proliferation assays, transwell migration and invasion studies, and flow cytometry-based apoptosis measurements. It also supports drug sensitivity testing with MEK inhibitors, synthetic lethal interaction screens, and functional genomic profiling. The pooled nature captures population-level heterogeneity, minimizing artifacts from single clonal expansion. For additional information, custom genome editing services, or technical consultation, please contact Ascent Research.
